Search Abstracts

Background Islatravir (ISL), a nucleoside reverse transcriptase (RT) translocation inhibitor, and lenacapavir (LEN), a capsid (CA) inhibitor, have pharmacokinetic profiles supportive of once-weekly (QW) oral dosing. GS-US-563-6041 (NCT05052996) is a Phase 2, open-label study evaluating QW ISL+LEN in virologically suppressed people with HIV-1. At Week (W) 48, ISL+LEN maintained high rates (94.2%) of viral suppression (VS;…

Background Antiretroviral therapy (ART) suppresses HIV replication and prevents the development of AIDS. However, ART is not curative. Persistence of viral reservoirs forms the major obstacle to an HIV cure. HIV reservoirs persist mainly through cellular longevity and proliferation, but replenishment by residual virus replication despite ART has been proposed as a potential mechanism of…

Background Reducing the number of active compounds for lifelong HIV treatment is of interest, especially to reduce potential long-term side effects. The Rumba study is the first randomized clinical trial evaluating the impact on the viral reservoir, inflammation and metabolic parameters of switch from a 2nd generation integrase inhibitor (INSTI)-based triple ART regimen towards DTG/3TC vs.…

Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen (STR) with no recommendations from the manufacturer regarding crushing or dissolving tablets for adult use. However, oral ingestion may be impractical for hospitalized individuals requiring enteral feeding. Despite some healthcare institutions administering B/F/TAF in crushed or dissolved form in such cases, there is limited clinical evidence regarding the efficacy…

Background For some individuals with HIV-1 infection who have failed multiple antiretroviral regimens and have limited treatment options, there is an urgent need for new antiretroviral drugs with novel mechanisms of action. Albuvirtide (ABT) is an HIV-1 fusion inhibitor and 3BNC117 is an HIV-specific, broadly neutralizing monoclonal antibody. We aimed to assess the efficacy and safety…

Background The high potency and genetic barrier of BIC/TAF/FTC (BETAF), and the long-half lives of their components could allow for longer than once-daily dosing (OD) with low risk of developing resistance mutations. We assessed the feasibility of reducing BETAF OD to 3 (3W), 2 (2W), or 1 (1W) doses per week. Methods Pilot randomized controlled…

Background We sought to examine reasons for discontinuation of long-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) and subsequent clinical outcomes in a cohort of people with HIV (PWH) in routine care. Methods We conducted a retrospective chart review of PWH who initiated LA-CAB/RPV at Ward 86 in San Francisco through April 2024, censoring data on September 23, 2024.…

Background Fostemsavir [FTR] is approved for use with other active antiretrovirals [ARVs] for treatment of heavily treatment-experienced people with HIV [PWH] and multi-drug resistance [MDR]. We described characteristics and treatment outcomes among PWH prescribed FTR in a real-world setting in the US.  Methods PWH initiating FTR from July 2020 (FDA approval) to June 2023 identified…

Background Sustained expression of adeno-associated virus (AAV)-vectored anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection. However, durable expression of AAV-vectored bNAbs in vivo is limited by host immune responses, impeding efficacy studies in preclinical nonhuman primate (NHP) models. Programmed cell death protein (PD)-1 is an immune checkpoint protein on T cells that…

Background Ensitrelvir, an oral main protease inhibitor targeting SARS-CoV-2, demonstrated robust antiviral activity in the phase 3 SCORPIO-HR/ACTIV-2d trial with a significant reduction in viral RNA levels and a higher percentage of negative viral cultures at Day 4 compared to placebo. In this exploratory analysis, we investigated emergence of resistance-associated mutations with ensitrelvir treatment.  Methods…